Dianthus Therapeutics insider exercises 15,000 options

Dianthus Therapeutics, Inc. insider activity: Adam M. Veness, SVP, General Counsel and Secretary, reported exercising stock options for 15,000 shares of common stock on August 13, 2026 at an exercise price of $18.17 per share.

Rhea-AI Filing Summary

Dianthus Therapeutics, Inc. insider activity: Adam M. Veness, SVP, General Counsel and Secretary, reported exercising stock options for 15,000 shares of common stock on August 13, 2026 at an exercise price of $18.17 per share. This converted a stock option into directly held common shares.

The derivative position of 15,000 option shares was disposed of upon exercise, leaving Veness with 73,240 derivative securities reported following the transaction. The option award vested 25% on June 20, 2024, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to his continued service.

Insider Trade Summary

15,000 shares exercised/converted

Exercise 2 txns

Insider Veness Adam M

Role SVP, General Counsel and Sec.

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy) F1	15,000	$0.00	$0.00
Exercise	Common Stock	15,000	$18.17	$273K

Holdings After Transaction: Stock Option (Right to Buy) — 73,240 contracts (Direct); Common Stock — 15,000 shares (Direct)

Footnotes (1)

1. F1. The shares of common stock underlying this stock option award vested as to 25% of the shares on June 20, 2024, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

Key Figures

Options Exercised: 15,000 shares Exercise Price: $18.17 per share Derivative Holdings After Exercise: 73,240 securities +4 more

7 metrics

Options Exercised 15,000 shares Stock option (right to buy) exercised on August 13, 2026

Exercise Price $18.17 per share Exercise or conversion price for the 15,000 stock options

Derivative Holdings After Exercise 73,240 securities Total derivative securities reported following the option exercise

Common Shares From Exercise 15,000 shares Common stock held directly after option exercise transaction

Option Expiration Date June 28, 2033 Expiration date of the stock option prior to exercise

Initial Vesting Date June 20, 2024 25% of the option vested on this date

Remaining Vesting Period 3 years Remaining 75% vests in equal monthly installments over three years

Key Terms

Stock Option (Right to Buy), derivative security, vesting, exercise price

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

derivative security financial

"transaction_code_description: Exercise or conversion of derivative security"

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

vesting financial

"underlying this stock option award vested as to 25% of the shares"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

exercise price financial

"conversion or exercise price: 18.1700"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did DNTH executive Adam M. Veness report?

Adam M. Veness reported exercising stock options for 15,000 shares of Dianthus Therapeutics common stock on August 13, 2026 at $18.17 per share, converting a derivative position into directly held common shares.

How many DNTH stock options did Adam M. Veness exercise and at what price?

He exercised 15,000 stock options, acquiring 15,000 shares of common stock at an exercise price of $18.17 per share. The exercise eliminated the corresponding option position tied to those shares.

What are Adam M. Veness’s reported holdings after the DNTH option exercise?

Following the transactions, one line shows 73,240 derivative securities remaining after the option exercise, and another shows 15,000 shares of common stock held directly, reflecting the newly acquired shares from the exercised options.

How does the DNTH stock option granted to Adam M. Veness vest?

The option vests 25% on June 20, 2024, with the remaining 75% vesting in equal monthly installments over the next three years, subject to his continued service to Dianthus Therapeutics on each vesting date.

Was the DNTH Form 4 transaction by Adam M. Veness a market sale or purchase?

The Form 4 reports a derivative exercise, not an open-market trade. Stock options were converted into 15,000 common shares at $18.17 per share, with no separate sale transaction reported in this filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/14/2026 - 04:30 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Veness Adam M

(Last) (First) (Middle)

C/O DIANTHUS THERAPEUTICS, INC.

7 TIMES SQUARE, 43RD FLOOR

(Street)

NEW YORK NEW YORK 10036

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Dianthus Therapeutics, Inc. /DE/ [ DNTH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, General Counsel and Sec.

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/13/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/13/2026		M		15,000	A	$18.17	15,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$18.17	08/13/2026		M			15,000	(1)	06/28/2033	Common Stock	15,000	$0	73,240	D

Explanation of Responses:

1. The shares of common stock underlying this stock option award vested as to 25% of the shares on June 20, 2024, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

	/s/ Adam Veness	08/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)